| Literature DB >> 31652501 |
Laura Guedes1, Pedro B P S Reis2, Miguel Machuqueiro3, Asma Ressaissi4, Rita Pacheco5,6, Maria Luísa Serralheiro7,8.
Abstract
Centaurium erythraea is recommended for the treatment of gastrointestinal disorders and to reduce hypercholesterolemia in ethno-medicinal practice. To perform a top-down study that could give some insight into the molecular basis of these bioactivities, decoctions from C. erythraea leaves were prepared and the compounds were identified by liquid chromatography-high resolution tandem mass spectrometry (LC-MS/MS). Secoiridoids glycosides, like gentiopicroside and sweroside, and several xanthones, such as di-hydroxy-dimethoxyxanthone, were identified. Following some of the bioactivities previously ascribed to C. erythraea, we have studied its antioxidant capacity and the ability to inhibit acetylcholinesterase (AChE) and 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGR). Significant antioxidant activities were observed, following three assays: free radical 2,2-diphenyl-1-picrylhydrazyl (DPPH) reduction; lipoperoxidation; and NO radical scavenging capacity. The AChE and HMGR inhibitory activities for the decoction were also measured (56% at 500 μg/mL and 48% at 10 μg/mL, respectively). Molecular docking studies indicated that xanthones are better AChE inhibitors than gentiopicroside, while this compound exhibits a better shape complementarity with the HMGR active site than xanthones. To the extent of our knowledge, this is the first report on AChE and HMGR activities by C. erythraea decoctions, in a top-down analysis, complemented with in silico molecular docking, which aims to understand, at the molecular level, some of the biological effects ascribed to infusions from this plant.Entities:
Keywords: Centaurium erythraea; HMG-CoA reductase; acetylcholinesterase; docking studies; gentiopicroside; xanthones
Mesh:
Substances:
Year: 2019 PMID: 31652501 PMCID: PMC6832739 DOI: 10.3390/molecules24203795
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Reversed-phase high-performance liquid chromatography with diode array detector (RP-HPLC–DAD) chromatogram of decoction of C. erythraea and its isolated fractions.
Figure 2Total ionic chromatogram and ionic chromatograms extracted from ions identified in C. erythraea complete decoction: (a) liquid chromatography–electrospray ionization tandem mass spectrometry (LC–ESI (−) MS/MS) and (b) LC–ESI (+) MS/MS. Peaks 1-7 are identified in Table 1.
Identification proposal of the compounds present in the complete decoction by LC–MS/MS in ESI negative and positive mode. Peaks with a minus/plus superscript were analyzed in negative/positive mode. Compounds are indicated by retention time (Rt) order and numbered according to the appearance in each chromatogram, negative [M − H]− or positive mode [M + H]+.
| Peak | Rt (min) | [M − H]−/[M + H]+ | Formula | Error (∆ ppm) | Main MS2 Fragment ions [ | Proposed Compound |
|---|---|---|---|---|---|---|
|
| 6.9 | 389.1102 | C16H22O11 | −3.1 | 345.1221 [C15H22O9]− (9); | Secologanoside |
|
| 7.7 | 551.1417 | C25H28O14 | −2.0 | 507.1517 [C24H28O12]− (66); | Caffeoyl-6′-secologa-noside |
|
| 8.1 | 641.1738 | C28H34O17 | −2.3 | 347.0776 [C17H16O8]− (59); | Di-hydroxy-tetrame-toxy - |
|
| 8.2 | 301.0362 | C15H10O7 | −2.7 | -- | Quercetin |
|
| 9.2 | 273.0413 | C14H10O6 | −3.1 | 258.0177 [C13H7O6]− (100); | Tri-hydroxy-monome-toxyxanthone |
|
| 10.3 | 287.0568 | C15H12O6 | −2.5 | 272.0335 [C14H9O6]− (22); | Di-hydroxy-dimetho-xyxanthone |
|
| 7.1 | 375.1275 | C16H22O10 | 2.9 | 195.0645 [C10H10O4]+ (9); | Swertiamarin |
|
| 7.1 | 357.1171 | C16H20O9 | 2.6 | 177.0538 [C10H8O3]+ (100); | Gentiopicroside |
|
| 7.2 | 359.1327 | C16H22O9 | 2.8 | 197.0798 [C10H12O4]+ (100); | Sweroside |
|
| 8.1 | 349.0909 | C17H16O8 | 2.6 | 334.0678 [C16H13O8]+ (7); | Di-hydroxy-tetrame-thoxyxanthone |
|
| 9.0 | 303.0857 | C16H14O6 | 1.9 | 288.0621 [C15H11O6]+ (100); | Monohydroxy-trime-toxyxanthone |
|
| 9.1 | 305.0643 | C15H12O7 | 4.2 | 290.0416 [C14H9O7]+ (86) | Tri-hydroxy-dimeto-xyxanthone |
Total phenols and bioactivities of the complete decoction (D) of C. erythraea, the decoction mucilage free (DMf), the xanthones fraction (XF) and the standard gentiopicroside.
| Extracts/Standard | Total Phenols (μg GAE/mg of Extract) | Antioxidant Activity | Enzyme Inhibitory Activity | |||
|---|---|---|---|---|---|---|
| DPPH (50 μg/mL) (%) | TBARS (400 μg/mL) (%) | EC50 NO’s (μg/mL) | AChE (500 μg/mL) (%) | HMGR (10 μg/mL) (%) | ||
| D | 22.37 ± 0.36 | 25.25 ± 0.72 | 32.23 ± 0.93 | 774.9 ± 13.8 | 56.43 ± 0.84 | 47.99 ± 0.47 |
| DMf | 18.82 ± 0.25 | 21.95 ± 0.46 | - | - | 47.09 ± 0.95 | - |
| XF | 16.31 ± 0.25 | 17.63 ± 0.41 | - | - | 59.81 ± 0.7 | 26.86 ± 0.87 |
| Gentio-picroside | - | 1.31±0.53 | - | - | 6.51 ± 0.18 | 57.95 ± 0.51 |
Figure 3Schematic structures: (a) gentiopicroside; (b) xanthone (template). The different substitutions in the R1–R8 positions, leading to the xanthone molecules used in the docking protocol, are described in Table 3.
Summary of all xanthones used in the AChE molecular docking calculations with their binding energies and inhibition constants. The R1-R8 positions relate to the xanthone template (Figure 3) and the OH/OMe labels refer to the hydroxyl and methoxy groups. The peaks refer to the positive and negative ESI modes in Table 1.
| Final Name | Peak | R1 | R2 | R3 | R4 | R5 | R6 | R7 | R8 | ΔGBIND (kcal/mol) | Ki (μM) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| xan01 * | 4+ | OH | OMe | OMe | OMe | OMe | OH | −6.0 | 36.9 | ||
| xan02 * | 4+ | OH | OMe | OMe | OH | OMe | OMe | −5.6 | 77.6 | ||
| xan03 * | 6+ | OH | OMe | OMe | OMe | −6.9 | 8.9 | ||||
| xan04 * | 6+ | OMe | OH | OMe | OMe | −6.6 | 15.3 | ||||
| xan05 * (decussatin) | 6+ | OH | OMe | OMe | OMe | −5.7 | 65.6 | ||||
| xan06 * | 6+ | OH | OMe | OMe | OMe | −5.9 | 50.9 | ||||
| xan07 * | 7+ | OH | OMe | OH | OMe | OH | −6.1 | 35.1 | |||
| xan08 * | 6− | OH | OMe | OH | OH | −7.5 | 2.9 | ||||
| xan09 * (bellidifolin) | 6− | OH | OMe | OH | OH | −7.5 | 2.9 | ||||
| xan10 * | 6− | OH | OMe | OH | OH | −6.5 | 17.0 | ||||
| xan11 * | 7− | OH | OMe | OMe | OH | −7.1 | 5.9 | ||||
| xan12 | 4+ | OH | OMe | OMe | OMe | OMe | OH | −7.5 | 3.4 | ||
| xan13 | 7+ | OH | OH | OH | OMe | OMe | −6.4 | 19.8 | |||
| xan14 | 6− | OH | OH | OMe | OH | −5.9 | 50.0 | ||||
| xan15 | 6− | OH | OH | OH | OMe | −7.5 | 3.0 | ||||
| xan08.1 | OH | OH | OH | OH | −7.3 | 4.2 | |||||
| xan08.2 | OH | OH | OH | −7.4 | 3.9 | ||||||
| xan08.3 | OH | OMe | OH | OH | OH | −7.1 | 6.0 | ||||
| xan09.1 | OH | OH | OH | OH | −7.4 | 3.5 | |||||
| xan09.2 | OH | OH | OH | −6.8 | 10.1 | ||||||
| xan12.1 | OH | OMe | OMe | OMe | OH | −7.9 | 1.6 | ||||
| xan12.2 | OH | OH | OMe | OMe | OMe | OH | −7.2 | 5.2 | |||
| xan12.3 | OH | OMe | OH | OMe | OMe | OH | −7.4 | 4.0 | |||
| xan12.4 | OH | OMe | OMe | OMe | OH | OH | −7.3 | 4.4 | |||
| xan15.1 | 7− | OMe | OH | OH | OMe | −6.7 | 12.3 |
* The position of substituent groups on the xanthone structure (Figure 2) indicated in this table was indicated in the literature: [15] for xan01, 02, 03, 04, 07, 08, 09, 10 and 11; [46] for xan01, 04, 05, 06 and 10; [47] for xan11.
Figure 4The lowest energy solutions from the docking calculations of gentiopicroside and the most active xanthones (cyan) in human AChE (green) are presented. Gentiopicroside (A) and xanthone 04 (B) are presented along with the X-ray structure of donepezil (PDB ID: 4EY7; [47]; dark grey) for a direct comparison. The interaction maps (black dashed lines) of gentiopicroside (C) and xanthones (D—xan03, E—xan04, F—xan09) in their best poses are also shown. The most active xanthone (xan09.1) differs from xan09 by removal of a methoxy group in the position R2 (highlighted with a black arrow—F). The catalytic residues of AChE are indicated with pink carbons. The active site pocket was calculated with hollow software [48] and represented as a gray surface.
Summary of all compounds used in the HMGR molecular docking calculations with their binding energies (ΔGBIND) and inhibition constants (Ki).
| Name | ΔGBIND (kcal/mol) | Ki (μM) |
|---|---|---|
| xan01 | −5.7 | 70.6 |
| xan03 | −5.5 | 98.9 |
| xan04 (bellidifolin) | −5.3 | 129.6 |
| xan07 | −5.1 | 184.8 |
| xan13 | −5.6 | 78.1 |
| xan08 | −5.6 | 78.1 |
| xan05 | −5.5 | 94.1 |
| xan12 | −5.7 | 71.8 |
| xan10 | −5.2 | 150.9 |
| xan14 | −5.7 | 70.6 |
| xan15 | −5.3 | 129.6 |
| xan06 | −5.3 | 131.8 |
| xan02 | −5.8 | 54.8 |
| xan11 | −5.4 | 102.3 |
| xan09 | −5.6 | 74.3 |
| gentiopiocroside | −6.4 | 19.9 |
| statin | −11.5 | 3.5 × 10−3 a) |
a) This is a corrected Ki value and is different from the one reported in [52], which had an error in the formula used.
Figure 5The lowest energy solutions from the docking calculations of a gentiopicroside (cyan—A) and xanthone 03 (pink—B) overlapped with the crystallographic structure of an atorvastatin derivative (yellow—1HW9); [53] in human HMGR (white carbons surface).